Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds

Abstract

The present invention provides a hemodialysis solution or concentrate thereof including creatine compound(s), the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof, a method for preparing creatine-containing dialysis solutions and concentrates, and a method for treating patients with dialysis dependent renal failure with creatine compounds to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells of the patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities. Furthermore, in peritoneal dialysis solutions creatine can be used as an osmotic agent preventing side effects caused by high glucose supplementation.

What is claimed: 
     
         1 . A dialysis concentrate for treating a patient with renal dysfunction, the concentrate comprising:
 at least one creatine compound; and   (ii) one or both of:
 (a) physiologically acceptable ions; and 
 (b) a physiologically acceptable buffering substance; 
   wherein said dialysis concentrate is formulated such that upon water dilution a resulting physiologically acceptable dialysis solution is obtained.   
     
     
         2 . The dialysis concentrate according to  claim 1 , wherein the physiologically acceptable buffering substance is present, and wherein said physiologically acceptable buffering substance has a basic pH. 
     
     
         3 . The dialysis concentrate according to  claim 1 , wherein the dialysis concentrate is essentially free of water prior to water dilution. 
     
     
         4 . The dialysis concentrate according to  claim 1 , wherein the dialysis concentrate is formulated such that upon water dilution by a factor of 25 to 60 by weight, the resulting physiologically acceptable dialysis solution has a concentration equivalent to from 0.002 to 45 mM/l creatine. 
     
     
         5 . The dialysis concentration according to  claim 1 , wherein the dialysis concentrate is in dry form. 
     
     
         6 . A dialysis concentrate for treating a patient with renal dysfunction, the concentrate comprising:
 (i) at least one creatine compound; and   (ii) one or more physiologically acceptable ions selected from the group consisting of Na-ions, K-ions, Ca-ions, Mg-ions and Cl-ions;   (iii) glucose; and   (iv) optionally, a physiologically acceptable buffering substance;   
       wherein said dialysis concentrate is formulated such that upon water dilution in the presence of at least one basic physiologically acceptable buffering substance a resulting physiologically acceptable dialysis solution is obtained having a pH in the range of 7.1 to 7.5. 
     
     
         7 . The dialysis concentrate according to  claim 6 , wherein the basic physiologically acceptable buffering substance is present in the dialysis concentrate. 
     
     
         8 . The dialysis concentrate according to  claim 6 , wherein the basic physiologically acceptable buffering substance is mixed with the dialysis concentrate during water dilution. 
     
     
         9 . The dialysis concentrate according to  claim 6 , wherein the dialysis concentrate is essentially free of water prior to water dilution. 
     
     
         10 . The dialysis concentrate according to  claim 6 , wherein the dialysis concentrate is formulated such that upon water dilution by a factor of 25 to 60 by weight, the resulting physiologically acceptable dialysis solution has a concentration equivalent to from 0.002 to 45 mM/l creatine. 
     
     
         11 . The dialysis concentration according to  claim 6 , wherein the dialysis concentrate is in dry form. 
     
     
         12 . A method for treating a patient with renal dysfunction, said method comprising:
 providing a dialysis solution having a concentration equivalent to from 0.002 to 45 mM/l creatine; and   administering the dialysis solution in a physiologically effective volume to the patient.   
     
     
         13 . The method according to  claim 12 , wherein in a first step a creatine compound is administered to the patient orally, and in a second step the dialysis solution is administered to the patient.